Pharmaceutical News

RSS

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Abiraterone has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel.

7 Jan 2012

Linagliptin does not offer added benefit for adults with type 2 diabetes

Linagliptin has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise.

7 Jan 2012

PCI Biotech focuses on localised cancer therapy with minimum side effects

Side effects are currently the biggest problem with any cancer treatment. A Norwegian biotech company is drawing closer to the goal of creating a treatment which kills only cancer cells, leaving other cells unaffected.

7 Jan 2012

USPTO issues patent to Tris Pharma's OralXR+ platform

Tris Pharma, an emerging specialty pharmaceutical company, announced the US grant of its core technology patent for its OralXR+ platform. This is the first patent grant of a substantial estate filed by Tris Pharma and covers a multitude of actives having modified release formulations comprising drug-ion exchange resin complexes.

7 Jan 2012

Supernus secures $42M through two transactions

Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million.

7 Jan 2012

CMS assigns permanent J-code for Savient's KRYSTEXXA to treat RCG

Savient Pharmaceuticals, Inc. today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA (pegloticase) became available on January 1, 2012.

7 Jan 2012

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo Pharmaceuticals announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine.

6 Jan 2012

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

BioDelivery Sciences International, Inc. today announced the signing of a worldwide license and development agreement with Endo Pharmaceuticals for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain.

6 Jan 2012

Statin use may influence susceptibility to ILD in smokers

Use of statins may influence susceptibility to or the progression of interstitial lung disease (ILD) in smokers, according to a new study.

6 Jan 2012

Researchers use qHTS approach to examine clinical drugs on thyroid cancer cells

Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective agents for thyroid cancer according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

6 Jan 2012

Oxytocin can make rhesus macaques pay more attention to each other

Oxytocin, the "love hormone" that builds mother-baby bonds and may help us feel more connected toward one another, can also make surly monkeys treat each other a little more kindly.

6 Jan 2012

UCSF appeals USPTO panel judgment in favor of InSite Vision

InSite Vision Incorporated today announced that the University of California, San Francisco (UCSF) has appealed the judgment of the United States Patent and Trademark Office (USPTO) panel that found in favor of the Company in its patent interference litigation with UCSF.

6 Jan 2012

Sanofi granted preliminary injunction to prevent launch of Seikagaku's Synvisc-One

Sanofi US today announced that the U. S. District Court in Massachusetts granted the company a preliminary injunction against a Synvisc-One (hylan G-F 20) competitor product developed by Seikagaku Corporation.

6 Jan 2012

Celtaxsys announces acquisition of CTX-4430 from Estrellita

Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.

6 Jan 2012

Cost paid for statins 400% higher in the U.S. than U.K.

In the United States, the cost paid for statins (drugs to lower cholesterol) in people under the age of 65 who have private insurance is approximately 400 percent higher than comparable costs paid by the government in the United Kingdom.

6 Jan 2012

Scientists identify how dihydromyricetin counteracts acute alcohol intoxication

UCLA researchers have identified how a component of an ancient Chinese herbal anti-hangover medicine called dihydromyricetin, isolated from the plant Hovenia, counteracts acute alcohol intoxication and withdrawal symptoms.

6 Jan 2012

New anti-tumor compounds show promise for hard-to-treat cancers

New anti-tumor compounds produced by Dr. Aleem Gangjee, Distinguished Professor of Medicinal Pharmacy at Duquesne University's Mylan School of Pharmacy, show such promise for fighting hard-to-treat tumors that the National Institutes of Health (NIH) has placed them on its fast track for development.

6 Jan 2012

Tetragenetics reports results from G-SOME H5N1 vaccine preclinical study

Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.

6 Jan 2012

Researchers identify potential target for schistosomiasis vaccine

In the complicated life cycle of ancient flatworms that cause schistosomiasis, Case Western Reserve University researchers have identified a gene activator crucial to development of the parasites within humans - a potential target for a vaccine.

6 Jan 2012

Combination of cancer drugs shows promise against Pompe disease

Kids with Pompe disease fail because of a missing enzyme, GAA, that leads to dangerous sugar build-up, which affects muscles and movement. An enzyme replacement treatment pioneered at Duke University has saved many lives, but some children with Pompe disease produce an immune reaction that blocks the benefits of the life-saving enzyme treatment.

6 Jan 2012